Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the specification:

Listing of Claims:

Claims 1-19 (cancelled)

Claim 20. (new) A method of treating mastocytosis, which comprises administering a therapeutically effective amount of the compound of formula (VII)



(VII)

or a pharmaceutically acceptable salt thereof,
to a human patient suffering from mastocytosis.

Claim 21. (new) A method according to claims 20, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100 % to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

Claim 22. (new) A method according to claim 20, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

Claim 23. (new) A method according to claim 20, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

Claim 24. (new) A method according to claim 20, wherein the compound of formula VII, is administered three times a day, for a total dose of 225 mg daily.

Claim 25. (new) A method according to claim 20, wherein the compound of formula VII is administered orally.

Claim 26. (new) A method according to claim 20, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

Claim 27. (new) A method according to claim 20, wherein up to 150 mg per day of the compound of formula VII is administered.

Claim 28. (new) A method according to claim 23, wherein the compound of formula VII is administered orally.

Claim 29. (new) A method according to claim 28, wherein the compound of formula VII is administered as a microemulsion.

Claim 30. (new) A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of the compound of formula (VII)



(VII)

or a pharmaceutically acceptable salt thereof,
to a patient suffering from mastocytosis with resistance to imatinib.

Claim 31. (new) A method according to claims 30, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100 % to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

Claim 32. (new) A method according to claim 30, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

Claim 33. (new) A method according to claim 30, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

Claim 34. (new) A method according to claim 30, wherein the patient has KIT tyrosine kinase receptor with a D816V mutation..

Claim 35. (new) A method according to claim 30, wherein the compound of formula VII is administered orally.

Claim 36. (new) A method according to claim 30, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

Claim 37. (new) A method according to claim 30, wherein up to 150 mg per day of the compound of formula VII is administered.

Claim 38. (new) A method according to claim 33, wherein the compound of formula VII is administered orally.

Claim 39. (new) A method according to claim 38, wherein the compound of formula VII is administered as a microemulsion.